Antonious Z. Hazim, MD
@AHazimMD
Followers
996
Following
1K
Statuses
382
Hematology Oncology Fellow at @MayoClinic | Thoracic malignancies, cellular therapies, phase 1 clinical trials | Views are my own 🫁 #oncology #cancer #lcsm
Mayo Clinic
Joined March 2019
First week of fellowship is off to a great start! Excited to work with this amazing team! @MayoClinic @MayoCancerCare @MayoHemeOnc
3
3
148
RT @dr_yakupergun: Long-Term Survival by ICIs in PD-L1–Negative mNSCLC 💥ICI-based therapy is more effective than ChT 💥In squamous histolo…
0
17
0
RT @ADesaiMD: In @JTOonline, LUPER: lurbinectedin + pembrolizumab in #SCLC 📊 • RR: 46.4% (3 CR) • DOR: 7.8m | PFS: 4.6m | OS: 10.5m 🔎 My T…
0
7
0
RT @StephenVLiu: Review in @JCOOP_ASCO on evolution of immunotherapy for #SCLC including first-line standards of care: IMpower133, CASPIAN,…
0
19
0
Herein, we review the current treatment paradigm of immunotherapy in SCLC and discuss future directions of this evolving field.
0
1
3
RT @OncoThor: What a time to be alive! Fantastic review of therapy options for NSCLC by @RManochakian . This and so much more at the Mayo H…
0
39
0
RT @KatsuakiMaehara: 🫁 Immunotherapy trials in resectable NSCLC 🫁 🌟 Updated clinical data as of January, 2025 🌟 KEYNOTE-671 - 4 year upda…
0
67
0
RT @DrJNaidoo: How do copy no. deletions in STK11, KEAP1 &SMARCA4 impact outcomes in NSCLC? -3194 nonsqNSCLCs: 14.7% STK11del 13.5% KEAP1d…
0
34
0
RT @DrJNaidoo: De-Escalation Strategies With ICIs in NSCLC: Do We Already Have Enough Evidence? @JCO_ASCO Pleased to contribute to this g…
0
20
0
RT @ElliotServaisMD: Fellow lung cancer providers: Who’s ready to try and memorize the 9th Ed staging which is now in place?! Some notable…
0
61
0
RT @triparnasen: Thrilled to announce our #ReviewArticle in @TheLancetOncol on #Pulmonary #Neuroendocrine #Neoplasms– hard-to-treat cancer…
0
25
0
RT @DrJNaidoo: Ph II TROPICS-03 trial: Sacituzumab Govitecan (TROP2 ADC) in 2L SCLC @JTOonline: - 43pts - ORR 41.9% (35% plt-resistant, 48…
0
20
0
RT @StephenVLiu: Perioperative osimertinib for resectable #EGFR NSCLC in the single institution NORA trial @JTOonline from @jii_bum_lee et…
0
23
0
RT @Ruah_Mahmoud: Proud to see this very important work by the absolutely amazing @RichGodby and the best, most awesome group being highlig…
0
1
0
RT @doctordegio: Our study in @LungCaJournal reveals the negative prognostic role of STK11 mutations in advanced NSCLC treated with first-…
0
8
0
Excited to present EVEREST-2! Phase 1/2 study of a MSLN Logic-Gated Tmod CAR T therapy in solid tumors. Honored to be a part of an incredible team at A2Bio. @MayoCancerCare @MayoHemeOnc
3
3
31